Pan Tumor Rollover Study

Description

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Conditions

Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Pan Tumor Rollover Study

Condition
Cancer
Intervention / Treatment

-

Contacts and Locations

Tucson

University of Arizona College of Medicine, Tucson, Arizona, United States, 85724

Lynwood

Innovative Clinical Research Institute, Lynwood, California, United States, 90262

San Francisco

Local Institution, San Francisco, California, United States, 94115

San Francisco

UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Melanoma Center, San Francisco, California, United States, 94143

Aurora

University of Colorado, Aurora, Colorado, United States, 80045

New Haven

Local Institution - 0095, New Haven, Connecticut, United States, 06520

Washington

Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States, 20007-2113

Ocala

Florida Cancer Affiliates, Ocala, Florida, United States, 34474

Orlando

Local Institution, Orlando, Florida, United States, 32806

Tampa

H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., Tampa, Florida, United States, 33612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Signed Written Informed Consent.
  • * Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
  • * On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
  • * WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.
  • * Participant is not eligible for study treatment per the Parent Study eligibility criteria.
  • * Participants not receiving clinical benefit as assessed by the Investigator.
  • * Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
  • * Other protocol-defined Inclusion/Exclusion Criteria apply

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bristol-Myers Squibb,

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

2029-08-25